AXNX Stock Overview
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$58.57|
|52 Week High||US$79.81|
|52 Week Low||US$38.41|
|1 Month Change||18.16%|
|3 Month Change||-0.46%|
|1 Year Change||-12.45%|
|3 Year Change||42.96%|
|5 Year Change||n/a|
|Change since IPO||290.99%|
Recent News & Updates
Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities
Axonics is a high-growth medical device play with strong revenue growth drivers. The company’s rechargeable SNM system generates the vast majority of its sales. Long-term investors can buy the company’s shares during pullbacks to maximize their gain.
Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|AXNX||US Medical Equipment||US Market|
Return vs Industry: AXNX exceeded the US Medical Equipment industry which returned -25.1% over the past year.
Return vs Market: AXNX exceeded the US Market which returned -20.5% over the past year.
|AXNX Average Weekly Movement||10.6%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: AXNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: AXNX's weekly volatility (11%) has been stable over the past year.
About the Company
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company’s SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction.
Axonics Fundamentals Summary
|AXNX fundamental statistics|
Is AXNX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AXNX income statement (TTM)|
|Cost of Revenue||US$65.78m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.70|
|Net Profit Margin||-41.28%|
How did AXNX perform over the long term?See historical performance and comparison
Is AXNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AXNX?
Other financial metrics that can be useful for relative valuation.
|What is AXNX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AXNX's PS Ratio compare to its peers?
|AXNX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: AXNX is expensive based on its Price-To-Sales Ratio (14.2x) compared to the peer average (10.3x).
Price to Earnings Ratio vs Industry
How does AXNX's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?
Price-To-Sales vs Industry: AXNX is expensive based on its Price-To-Sales Ratio (14.2x) compared to the US Medical Equipment industry average (3.8x)
Price to Sales Ratio vs Fair Ratio
What is AXNX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||14.2x|
|Fair PS Ratio||6.8x|
Price-To-Sales vs Fair Ratio: AXNX is expensive based on its Price-To-Sales Ratio (14.2x) compared to the estimated Fair Price-To-Sales Ratio (6.8x).
Share Price vs Fair Value
What is the Fair Price of AXNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AXNX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AXNX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AXNX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Axonics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AXNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AXNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AXNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AXNX's revenue (19.2% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: AXNX's revenue (19.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AXNX is forecast to be unprofitable in 3 years.
Discover growth companies
How has Axonics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AXNX is currently unprofitable.
Growing Profit Margin: AXNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AXNX is unprofitable, and losses have increased over the past 5 years at a rate of 26.3% per year.
Accelerating Growth: Unable to compare AXNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AXNX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: AXNX has a negative Return on Equity (-17.31%), as it is currently unprofitable.
Discover strong past performing companies
How is Axonics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AXNX's short term assets ($307.4M) exceed its short term liabilities ($25.5M).
Long Term Liabilities: AXNX's short term assets ($307.4M) exceed its long term liabilities ($36.6M).
Debt to Equity History and Analysis
Debt Level: AXNX is debt free.
Reducing Debt: AXNX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AXNX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AXNX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.2% each year
Discover healthy companies
What is Axonics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AXNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AXNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AXNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AXNX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AXNX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ray Cohen (62 yo)
Mr. Raymond W. Cohen, also known as Ray, has been the Chief Executive Officer and Director of Axonics Inc. since October 2013. Mr. Cohen, an accredited public company Director, has experience leading and g...
CEO Compensation Analysis
Compensation vs Market: Ray's total compensation ($USD5.57M) is about average for companies of similar size in the US market ($USD6.92M).
Compensation vs Earnings: Ray's compensation has increased whilst the company is unprofitable.
Experienced Management: AXNX's management team is seasoned and experienced (6.4 years average tenure).
Experienced Board: AXNX's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
Axonics, Inc.'s employee growth, exchange listings and data sources
- Name: Axonics, Inc.
- Ticker: AXNX
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$2.757b
- Shares outstanding: 47.07m
- Website: https://www.axonics.com
Number of Employees
- Axonics, Inc.
- 26 Technology Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.